NCT00217139已完成2 期
A Phase II, Randomized, Active-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With and Without Ribavirin, for 12 Weeks in Patients With Chronic Hepatitis C Infection (Genotype 1) Who Failed to Respond to Pegylated α Interferon-Based Therapy
BioWest Therapeutics Inc6 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2005年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 6
- 主要终点
- Safety analysis
研究概览
简要总结
The objective of the study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-65 years of age, inclusive
- •primary diagnosis of chronic HCV infection
- •non-responders to previous pegylated interferon-based therapy
排除标准
- •patients naive to interferon-based therapy for chronic HCV infection
结局指标
主要结局
Safety analysis
HCV viral load
次要结局
未报告次要终点
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 InfectionHepatitis C, ChronicNCT00157534BioWest Therapeutics Inc43
已完成
2 期
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)Hepatitis CHIV InfectionsNCT00008463National Institute of Allergy and Infectious Diseases (NIAID)132
已完成
3 期
Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C PatientsChronic Hepatitis CNCT01581398Xiamen Amoytop Biotech Co., Ltd.770
已完成
3 期
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)Chronic Hepatitis CLiver CirrhosisNCT00304551Chugai Pharmaceutical180
已完成
4 期
A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis CHepatitis C, ChronicNCT00800748Hoffmann-La Roche372